Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Esmya rejection hits Allergan's streamlining
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
